Logo
Eloquence Deep Lidocaine

Eloquence Deep Lidocaine

Eloquence

Dermal filler – hyaluronic acid injectable
  • Eloquence hyaluronic acid dermal fillers are described by multiple distributors and promotional materials as CE Certified medical devices for aesthetic use in Europe and the UK.
  • Manufactured by Jetema, a Korean biopharmaceutical and beauty company founded in 1999, which also produces other HA filler brands such as Regenovue and e.p.t.q., and states adherence to stringent quality standards for filler production.
  • Product information from European distributors describes Medical Class II classification for Eloquence Deep within the EU medical device framework.
  • Production uses ZEEP (Zero Endotoxin & BDDE Entire Process) technology and an aseptic manufacturing environment, with reported endotoxin levels below 0.1 EU/ml and minimised residual BDDE.
  • Manufacturing and quality management are described as compliant with high standards for HA filler production, in line with ISO Based quality systems for medical devices (e.g. ISO 13485), as referenced in distributor technical literature.
Deep hyaluronic acid dermal filler with lidocaine for facial volumisation

Description

Eloquence Deep Lidocaine is a CE-marked, high-elasticity hyaluronic acid dermal filler with lidocaine, produced by the Korean biopharmaceutical and beauty company Jetema. It is a dense, longer-lasting monophasic gel specifically designed for the correction of medium to deep wrinkles and folds (such as nasolabial folds) and for volumetric contouring and augmentation of the cheeks, chin, forehead, nose and lips. With a hyaluronic acid concentration of 24 mg/ml and lidocaine 0.3% (3 mg/ml), the filler provides structural support and natural-looking volume while the lidocaine improves comfort during injection. Results are typically long-lasting, with many distributors reporting effects in the range of approximately 12 to 18 months depending on patient factors and treatment area.

Bnefits

  • High-elasticity hyaluronic acid filler specifically formulated for medium to deep wrinkles and volumetric contouring.
  • Densely structured gel provides effective lifting, volumisation and long-lasting correction.
  • Suitable for augmenting and defining cheeks, chin, forehead, nose and lips, as well as treating deep nasolabial folds and other deep facial lines.
  • Contains lidocaine (0.3%) to reduce pain and discomfort during injection and improve overall treatment experience.
  • High viscoelasticity and cohesiveness support natural tissue integration and stable aesthetic outcomes.
  • Low endotoxin level (reported <0.1 EU/ml) and optimised cross-linking process designed to minimise swelling and reduce risk of adverse reactions.
  • Monophasic gel and optimised injection pressure support smooth, controlled administration and precise contouring.
  • CE-certified hyaluronic acid filler manufactured according to stringent quality and safety criteria (including ZEEP technology – Zero Endotoxin & BDDE Entire Process).
  • Long duration of effect, with many sources indicating results can last from approximately 12 up to 18 months depending on individual factors.

Indications

  • Correction of medium to deep facial wrinkles and folds, including nasolabial folds.
  • Volumetric augmentation and contouring of the cheeks and cheekbones.
  • Chin augmentation and contouring to improve facial harmony and profile.
  • Forehead and temple volumisation where indicated by an appropriately trained practitioner.
  • Non-surgical nose reshaping (non-surgical rhinoplasty) in experienced hands.
  • Lip augmentation and definition for patients requiring a slightly denser, longer-lasting gel.
  • Filling of deeper skin depressions and volume deficits in the mid-face, lower face and perioral region, as judged suitable by the treating clinician.

Composition

  • Hyaluronic acid (cross-linked) 24 mg/ml (non-animal origin).
  • Lidocaine hydrochloride 0.3% (3 mg/ml) as a local anaesthetic.
  • Physiological buffer solution with pH and osmolarity adjusted to approximate human tissue (exact excipient list not publicly disclosed; typical components include phosphate-buffered saline and stabilising agents).
  • Endotoxin content less than 0.1 EU/ml, according to manufacturer information for the Eloquence range.
  • Residual BDDE (cross-linking agent) minimised through ZEEP (Zero Endotoxin & BDDE Entire Process) technology; the Degree of Modification (MoD) is stated to be lower than for many comparable fillers while maintaining high viscoelasticity.

Formulation

  • Monophasic, cross-linked hyaluronic acid gel with lidocaine for injectable implantation.
  • Hyaluronic acid concentration: 24 mg/ml.
  • Lidocaine concentration: 0.3% (3 mg/ml).
  • Syringe volume: pre-filled 1.1 ml sterile, disposable syringe.
  • Supplied with 2 x 27G sterile needles per box (according to multiple distributors).
  • Highly elastic, cohesive gel designed for deep dermal and/or subcutaneous injection depending on indication and practitioner technique.
  • Medical device classification noted by some distributors as Medical Class II (within the broader CE-marked HA filler category).

Packaging

  • Single-use, pre-filled glass syringe containing 1.1 ml of cross-linked hyaluronic acid gel with lidocaine.
  • Each unit box typically contains 1 syringe and 2 x 27G sterile needles, packed in a blister tray.
  • Outer carton printed with product name (Eloquence Deep), volume, batch number, expiry date and CE mark.
  • Sterile, pyrogen-free, single-use device intended for use by trained medical/aesthetic professionals only.

Usage

  • Eloquence Deep Lidocaine must only be used by appropriately trained and qualified medical or aesthetic practitioners with knowledge of facial anatomy, injection techniques and filler complication management.
  • Before treatment, a full medical history, indications assessment and informed consent should be completed; pre-treatment photographs are generally recommended.
  • Cleanse and disinfect the treatment area according to clinical protocol. Additional topical anaesthetic may be used at the practitioner’s discretion, bearing in mind that the filler contains lidocaine.
  • Select appropriate injection technique (e.g. linear threading, serial puncture, fanning, depot) and depth (typically deep dermis or subcutaneous plane depending on area and indication). Needle or cannula choice and insertion angle should be in line with current best practice and manufacturer/distributor training materials.
  • Inject slowly using minimal pressure, monitoring tissue response and symmetry throughout. Avoid intravascular injection by aspirating according to the practitioner’s protocol and constantly assessing patient feedback and visual cues.
  • Massage gently as required to mould the product and achieve a smooth, even contour, avoiding excessive pressure that might displace the filler.
  • Total volume per session and per area should be adapted to indication, patient anatomy and safety guidelines; overcorrection should be avoided.
  • After treatment, provide patients with written aftercare advice, including recommendations to avoid extreme heat or cold, strenuous exercise, and makeup on treated areas for the period advised by the practitioner.
  • Ensure patients understand the signs and symptoms of potential complications (e.g. vascular compromise, severe pain, blanching, unusual discolouration or visual changes) and the need for urgent review if they occur.
  • Store and handle the product in accordance with the manufacturer’s instructions and do not use if the packaging is damaged, opened or past the expiry date.

Contraindications

  • Known hypersensitivity to hyaluronic acid, lidocaine or other amide-type local anaesthetics, or to any of the excipients.
  • Patients with a history of severe allergy or anaphylactic reactions to injectable products unless adequately assessed and managed by an experienced clinician.
  • Presence of active skin infections, inflammation or lesions (e.g. acne, herpes simplex) at or near the intended injection sites.
  • History of autoimmune disease or immune system disorders where dermal filler treatment is deemed inappropriate by the prescribing clinician.
  • Concomitant use of certain medications that may increase bleeding risk (e.g. high-dose anticoagulants) unless risks and benefits have been carefully evaluated.
  • Known bleeding disorders or coagulation abnormalities that significantly increase the risk of bruising or haematoma, unless specialist advice has been obtained.
  • Pregnancy and breastfeeding – dermal fillers containing hyaluronic acid with lidocaine are generally not recommended due to lack of sufficient safety data.
  • Known tendency to develop hypertrophic scars or keloids, or significant connective tissue disorders, unless deemed appropriate by a specialist.
  • Previous permanent fillers or certain semi-permanent products in the same area, where there is a risk of interactions or nodularity.
  • Any other condition or circumstance that, in the professional judgement of the treating clinician, makes dermal filler injection inappropriate or unsafe.

Adverse Effects

  • Common, usually transient injection-site reactions such as redness (erythema), swelling, tenderness, pain, itching, bruising or slight discolouration at the injection site; these typically resolve within days.
  • Palpable lumps, nodules or unevenness at the treatment area if the gel is not evenly distributed or if localised overfilling occurs; often manageable with massage or, if persistent, with hyaluronidase by trained clinicians.
  • Temporary firmness or a feeling of fullness in the treated area as the product integrates with tissue.
  • Allergic or hypersensitivity reactions, including localised swelling or more generalised responses; these are uncommon but require prompt management.
  • Infection at the injection site if aseptic technique is not correctly followed or in susceptible patients; may present with warmth, pain, redness and swelling.
  • Vascular compromise or occlusion if the filler is inadvertently injected intravascularly or causes external vessel compression; signs may include severe pain, blanching, livedo or tissue discolouration and require immediate emergency management, including use of hyaluronidase and other measures according to established complication protocols.
  • Very rare but serious events reported for HA fillers in general, such as visual disturbances, blindness or stroke in cases of embolic vascular occlusion; practitioners must be trained in prevention, recognition and emergency response.
  • Delayed inflammatory reactions, granuloma formation or biofilm-related issues have been reported rarely with hyaluronic acid dermal fillers and may require medical treatment.
  • Transient numbness or altered sensation due to lidocaine content or injection trauma, usually resolving spontaneously.

Storage Conditions

  • Store at a controlled room temperature as specified by the manufacturer (commonly between 2 °C and 25 °C); avoid freezing.
  • Keep the syringe in its original blister and outer carton until use to protect from light and contamination.
  • Do not use the product after the expiry date printed on the packaging.
  • Do not use if the blister, syringe or needle packaging is opened, damaged or compromised.
  • Store out of the reach and sight of unauthorised persons and children, in accordance with local regulations for medical devices.
  • Dispose of used syringes, needles and any unused product in accordance with local clinical sharps and medical waste procedures.

Duration

According to multiple distributor sources, the aesthetic effects of Eloquence Deep generally last from approximately 12 to 18 months, with some sources giving a broader range of 6 to 18 months depending on factors such as the treatment area, injection technique, patient metabolism, lifestyle and age. Touch-up or maintenance treatments may be performed at the clinician\u2019s discretion once results begin to diminish.

Onset

Volume restoration and wrinkle correction are typically visible immediately after injection, with final results becoming more stable over several days as initial swelling subsides and the product integrates with the surrounding tissues. Patients should be reviewed after the initial healing period to assess results and need for any refinement.

Browse more Dermal filler \u2013 hyaluronic acid injectable

Top Treatments

Top Cities in the UK